Search Result

Results for "

immunoglobulin G1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ADC Antibody (2) ANGPTL (1) Antibiotic (1) Apoptosis (1) Bacterial (2) Biochemical Assay Reagents (1) c-Kit (1) Caspase (1) CCR (1) CD20 (1) CD276/B7-H3 (1) CD28 (1) CD3 (3) Claudin (1) Complement System (4) CTLA-4 (3) CXCR (1) EGFR (1) GLP Receptor (1) IFNAR (1) IGF-1R (1) Interleukin Related (2) NTPDase (1) Orexin Receptor (OX Receptor) (1) PD-1/PD-L1 (1) Phosphodiesterase (PDE) (1) TGF-β Receptor (1) Tie (1) TNF Receptor (3) Transmembrane Glycoprotein (2) VEGFR (1) Virus Protease (1)
By Research Areas:	Cancer (20) Cardiovascular Disease (1) Endocrinology (1) Infection (3) Inflammation/Immunology (21) Metabolic Disease (5) Neurological Disease (1)

By Targets:

ADC Antibody (2)

ANGPTL (1)

Antibiotic (1)

Apoptosis (1)

Bacterial (2)

Biochemical Assay Reagents (1)

c-Kit (1)

Caspase (1)

CCR (1)

CD20 (1)

CD276/B7-H3 (1)

CD28 (1)

CD3 (3)

Claudin (1)

Complement System (4)

CTLA-4 (3)

CXCR (1)

EGFR (1)

GLP Receptor (1)

IFNAR (1)

IGF-1R (1)

Interleukin Related (2)

NTPDase (1)

Orexin Receptor (OX Receptor) (1)

PD-1/PD-L1 (1)

Phosphodiesterase (PDE) (1)

TGF-β Receptor (1)

Tie (1)

TNF Receptor (3)

Transmembrane Glycoprotein (2)

VEGFR (1)

Virus Protease (1)

By Research Areas:

Cancer (20)

Cardiovascular Disease (1)

Endocrinology (1)

Infection (3)

Inflammation/Immunology (21)

Metabolic Disease (5)

Neurological Disease (1)

Inhibitors & Agonists

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Targets Recommended: Human leukocyte immunoglobulin (Ig)-like receptors (LILR) LILRB Tim3

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-127105

Iptacopan Maximum Cited Publications 13 Publications Verification LNP023	Complement System	Metabolic Disease Inflammation/Immunology
Iptacopan (LNP023) is an effective and orally-active highly selective factor B inhibitor with an IC₅₀ value of 10 nM and K_D of 7.9 nM. Iptacopan exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .

HY-P99955

Rocatinlimab AMG 451; KHK4083	Orexin Receptor (OX Receptor)	Infection Inflammation/Immunology
Rocatinlimab (AMG 451) (KHK4083) is a fully human immunoglobulin G1 (IgG1) anti-OX40 monoclonal antibody. Rocatinlimab can be used for the research of atopic dermatitis (AD) .

HY-P99367

Ifinatamab DS-7300a Antibody; MABX-9001A Antibody	CD276/B7-H3	Inflammation/Immunology Cancer
Ifinatamab is monoclonal immunoglobulin G1-kappa with anti-human B7 homolog 3 protein (Human B7-H3). Ifinatamab is a glycoforme α immunomodulateur .

HY-P99033

Mosunetuzumab 1 Publications Verification BTCT-4465A; RG-7828; RO7030816	CD20 CD3	Inflammation/Immunology Cancer
Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .

HY-127105A

Iptacopan hydrochloride Maximum Cited Publications 13 Publications Verification LNP023 hydrochloride	Complement System	Metabolic Disease Inflammation/Immunology
Iptacopan (LNP023) hydrochloride is an effective and orally-active highly selective factor B inhibitor with an IC₅₀ value of 10 nM and K_D of 7.9 nM. Iptacopan hydrochloride exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan hydrochloride can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .

HY-P9920A

Ramucirumab (anti-VEGFR) 1 Publications Verification	VEGFR	Cancer
Ramucirumab (anti-VEGFR) is a human VEGFR-2 antagonist for the treatment of solid tumors. Ramucirumab (anti-VEGFR) is a recombinant human immunoglobulin G1 monoclonal antibody that binds to the extracellular binding domain of VEGFR-2 and prevents the binding of VEGFR ligands: VEGF-A, VEGF-C, and VEGF-D. Ramucirumab (anti-VEGFR) is also an angiogenesis inhibitor .

HY-P99550

Tozorakimab 1 Publications Verification MEDI-3506	Interleukin Related	Inflammation/Immunology
Tozorakimab (MEDI-3506) is a human immunoglobulin G1 monoclonal antibody targeting interleukin-33. Tozorakimab reduces inflammation and epithelial dysfunction. Tozorakimab can be used to research chronic obstructive pulmonary disease .

HY-P99521

Vibecotamab XmAb14045	CD3	Inflammation/Immunology Cancer
Vibecotamab (XmAb14045) is a potent bispecific antibody targeting both CD123 and CD3. Vibecotamab targets T cell-mediated killing of CD123-expressing cells, regardless of T cell antigen specificity. Vibecotamab is a full length immunoglobulin molecule. Vibecotamab can be studied in research for diseases such as Myelodysplastic syndrome and acute myeloid leukemia. Recommend Isotype Control: half-IG G1-kappa/(scFv-heavy-lambda)-h-CH2-CH3 .

HY-P990047

Maridebart AMG133 antibody	ADC Antibody GLP Receptor	Metabolic Disease
Maridebart (AMG133 antibody) is a human immunoglobulin G1-kappa, anti-GIPR (gastric inhibitory polypeptide receptor) monoclonal antibody. Maridebart is the antibody portion of Maridebart cafraglutide (HY-164535) and can be used for the synthesis of antibody-drug conjugates (ADC). Maridebart can be used for the reserrch of obesity and type 2 diabetes .

HY-P99036

Nesvacumab	Tie	Cardiovascular Disease Inflammation/Immunology Cancer
Nesvacumab is a fully human immunoglobulin G1 (IgG1) monoclonal antibody that specifically binds and inactivates the Tie2 receptor ligand Angiopoietin-2 (Ang2) with high affinity, but shows no binding to Ang1. Nesvacumab can be used in vascular researches .

HY-P99934

Eftozanermin alfa 1 Publications Verification ABBV-621	Apoptosis Caspase TNF Receptor	Cancer
Eftozanermin alfa (ABBV-621) is a tumor necrosis factor-related apoptosis-inducing ligand receptor (TRAIL-R) agonist. Eftozanermin alfa is a fusion protein consisting of a mutant immunoglobulin G1-Fc linked to 2 single-chain trimers of TRAIL. Eftozanermin alfa induces apoptosis in tumor cells by activation of death receptors (DR4 receptor and DR5 receptor) with K_ds of 780 nM and 635 nM. Eftozanermin alfa can be used for the research of multiple solid and heme malignancies .

HY-P990045

Lixudebart ALE.F02	Claudin	Endocrinology
Lixudebart (ALE.F02) is a humanized immunoglobulin G1-kappa, anti-CLDN1 monoclonal antibody. Lixudebart disrupts CLDN1 interactions with CD44 and MMP14, reduces renal macrophage infiltration, epithelial activation, and urinary albumin-to-creatinine ratio, and attenuates glomerulosclerosis. Lixudebart can be used for the research of focal segmental glomerulosclerosis .

HY-P990032

Belrestotug EOS-448; EOS884448; GSK4428859A	Transmembrane Glycoprotein	Inflammation/Immunology Cancer
Belrestotug (EOS-448) is an antagonistic anti-TIGIT (VSIG9, VSTM3) human immunoglobulin G1 kappa (hIgG1 kappa) antibody. Belrestotug shows antineoplastic activity. Belrestotug can be used for cancer and immunological research such as colon cancer .

HY-P990021

Calpurbatug TRL1068	Bacterial	Others
Calpurbatug is an immunoglobulin G1 antibody. Calpurbatug has activity with anti-bacterial DNA-binding protein DNABII family and anti-human monoclonal TRL1068 γ1-chain .

HY-P99551

Tosatoxumab KBSA301; AR-301	Antibiotic Bacterial	Infection
Tosatoxumab (AR-301; KBSA301) is a human immunoglobulin G1 monoclonal antibody that specifically neutralizes alpha-toxin (alpha-hemolysin; Hla) of S. aureus. Tosatoxumab binds to an N-terminal epitope of alpha-toxin, thereby preventing functional toxin pore oligomerisation. Tosatoxumab has the potential for passive immunotherapy in the S. aureus pneumonia as an adjunctive therapy to standard antibiotic agent. Recommend Isotope Control: Human IgG1 lambda1, Isotype Control (HY-P99992) .

HY-P991661

AMG-172 Antibody	ADC Antibody TNF Receptor Transmembrane Glycoprotein	Cancer
AMG-172 Antibody is an anti-CD27L antibody. AMG-172 Antibody can be used for synthesis of ADC AMG-172 (HY-185483) .

HY-163480

PF-06835375	CXCR	Inflammation/Immunology
PF-06835375 is a selective, humanized CXCR5-targeting immunoglobulin G1 antibody. PF-06835375 depletes CXCR5-positive B cells, follicular helper T cells and circulating Tfh-like cells. PF-06835375 is applicable to research related to autoimmune diseases .

HY-P990048

Muzastotug ADG126	CTLA-4	Cancer
Muzastotug is a humanized immunoglobulin G1-kappa, anti-CTLA4 monoclonal antibody. Muzastotug is an immunostimulant and antineoplastic .

HY-P990079

Renvistobart BMS-986207; ONO-4686	CD28	Inflammation/Immunology
Renvistobart is an immunoglobulin G1-κ, anti-[Homo sapiens TIGIT (T cell immunoreceptor with Ig domain and ITIM, VSIG9, VSTM3)] Homo sapiens monoclonal antibody .

HY-P991706

Nelvutamig	Phosphodiesterase (PDE) CD3	Cancer
Nelvutamig is a humanized immunoglobulin (H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3) antibody targeting ENPP3/CD203c and CD3E. The corresponding isotype control is: Human immunoglobulin (H-gamma1_L-kappa)_scFvkh-G1(h-CH2-CH3) .

HY-P99698

Lesabelimab LDP	PD-1/PD-L1	Inflammation/Immunology Cancer
Lesabelimab (LDP) is an immunoglobulin G1-kappa anti-CD274 monoclonal antibody. CD274 is an immune checkpoint ligand, represses antitumour immunity through the interaction with PDCD1 receptor .

HY-P991678

Efpixileukin alfa XENP-27564; XMAB-27564	Interleukin Related	Inflammation/Immunology
Efpixileukin alfa is a fusion protein that combines human IL-2 variant fused at the C-terminus to human immunoglobulin G1 (IgG1) Fc fragment. Efpixileukin alfa is an immunomodulator .

HY-NP0196A

*Mouse Immunoglobulin* G1**	Biochemical Assay Reagents	Inflammation/Immunology
Mouse Immunoglobulin G1 is a mouse serum immunoglobulin that can be used in immunolabeling and coating protein in a variety of immunoassays including ELISA .

HY-P990020

Eglatoprutug FSI-174	c-Kit	Others
Eglatoprutug is an humanized immunoglobulin *G1-kappa, anti-c-Kit* monoclonal antibody .

HY-147407

Imbotolimod	EGFR	Cancer
Imbotolimod, immunoglobulin G1-kappa, is a humanized monoclonal antibody with anti-ERBB2 and antineoplastic activity. Imbotolimod is a derivative of telratolimod .

HY-P991135

Enzelkitug RO-7502175; RG-6411	CCR	Cancer
Enzelkitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the human C-C motif chemokine receptor 8 (CCR8). Enzelkitug is promising for research of various solid tumors and hematological malignancies .

HY-P991153

Potravitug	Virus Protease	Infection
Potravitug is a humanized immunoglobulin G1-κ monoclonal antibody targeting the major capsid protein VP1 of BK polyomavirus (BKV). Potravitug is promising for research of BKV-infection-related diseases, such as BKV-induced nephropathy after organ transplantation .

HY-P991195

SIM-0235 SIM1811-03	TNF Receptor	Cancer
SIM-0235 is humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets and inhibits TNFR2, the recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001) ^[1].

HY-P991134

Elegrobart	IGF-1R	Inflammation/Immunology
Elegrobart is an immunoglobulin G1-κ monoclonal antibody targeting the human insulin-like growth factor 1 receptor (IGF1R). Elegrobart is promising for research of diseases associated with abnormal IGF1R signaling, especially thyroid eye disease .

HY-P991158

Rinvatercept	TGF-β Receptor	Neurological Disease
Rinvatercept, a fusion protein, is a glycyl (1)-chimeric N-terminal (1-108)-peptide (2-109) combined from the sequences of the extracellular domains of the human ACVR2A/B, and is fused via a G3 peptide linker (110-112) to an immunoglobulin G1 (IgG1) Fc fragment. Rinvatercept can be used for research of neuromuscular disease .

HY-P990080

Sovipostobart BMS-986249	CTLA-4	Cancer
Sovipostobart is an immunoglobulin G1-kappa, anti-CTLA-4 human monoclonal antibody with cleavable prodomain. Sovipostobart is an immunostimulant and antineoplastic .

HY-P991139

Futermestotug	CTLA-4	Cancer
Futermestotug is a humanized immunoglobulin G1-κ monoclonal antibody targeting human cytotoxic T-lymphocyte associated protein 4 (CTLA4). Futermestotug is promising for research of various malignant tumors .

HY-200854

Iptacopan hydrochloride hydrate LNP023 hydrochloride hydrate	Complement System	Metabolic Disease Inflammation/Immunology
Iptacopan (LNP023) hydrochloride hydrate is an effective and orally-active highly selective factor B inhibitor with an IC₅₀ value of 10 nM and K_D of 7.9 nM. Iptacopan hydrochloride hydrate exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan hydrochloride hydrate can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .

HY-P992105

Corveldebart	ANGPTL	Inflammation/Immunology
Corveldebart is a monoclonal antibody of immunoglobulin G1-kappa that targets ANGPTL4. Corveldebart can be used as an immunomodulator .

HY-P992099

Afivastobart AB598	NTPDase	Cancer
Afivastobart (AB598) is a human ENTPD1 (CD39)-targeting monoclonal antibody with antineoplastic activity.Afivastobart binds as a monoclonal antibody to modulate Homo sapiens ENTPD1 activity.Afivastobart constitutes a glycoform alfa immunoglobulin G1-kappa monoclonal antibody .

HY-P992394

JNJ-55920839 CNTO-6358	IFNAR	Inflammation/Immunology
JNJ-55920839 (CNTO-6358) is a fully human immunoglobulin G1κ monoclonal antibody and a selective Interferon α/ω neutralizer, with a K_d value of 0.9-10.7 pM against hIFNα and a K_d of 1.44 pM against IFNω. JNJ-55920839 can be used in research related to systemic lupus erythematosus .

HY-127105B

Iptacopan TFA LNP023 TFA	Complement System	Metabolic Disease Inflammation/Immunology
Iptacopan (LNP023) TFA is an effective and orally-active highly selective factor B inhibitor with an IC₅₀ value of 10 nM and K_D of 7.9 nM. Iptacopan TFA exerts a proximal effect in the complement cascade reaction, preventing the destruction (hemolysis) of red blood cells in PNH and the damage of renal cells in IgAN and C3G. Iptacopan TFA can be used for the study of complement-mediated diseases, particularly paroxysmal nocturnal hemoglobinuria (PNH), primary immunoglobulin A nephropathy (IgAN), and complement 3 glomerulopathy (C3G) .

*Mouse Immunoglobulin* G1**	Biochemical Assay Reagents
Mouse Immunoglobulin G1 is a mouse serum immunoglobulin that can be used in immunolabeling and coating protein in a variety of immunoassays including ELISA .

Cat. No.	Product Name	Target	Research Area

HY-P60128

TTP	Peptides	Others
TTP is a generic surrogate peptide. TTP can be used for quantitative analysis of a recombinanthuman immunoglobulin G1 (hIgG1) in rat serum .

Cat. No.	Product Name	Target	Research Area	Image